452 related articles for article (PubMed ID: 33307015)
1. Meta-Analysis Evaluating the Efficacy and Safety of Low-Intensity Warfarin for Patients >65 Years of Age With Non-Valvular Atrial Fibrillation.
Kang F; Ma Y; Cai A; Cheng X; Liu P; Kuang J; Mai Z; Mai W
Am J Cardiol; 2021 Mar; 142():74-82. PubMed ID: 33307015
[TBL] [Abstract][Full Text] [Related]
2. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Deng Y; Tong Y; Deng Y; Zou L; Li S; Chen H
J Am Heart Assoc; 2019 Jul; 8(14):e012540. PubMed ID: 31310583
[TBL] [Abstract][Full Text] [Related]
3. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
[TBL] [Abstract][Full Text] [Related]
4. Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study.
Chan EW; Lau WC; Siu CW; Lip GY; Leung WK; Anand S; Man KK; Wong IC
Heart Rhythm; 2016 Aug; 13(8):1581-8. PubMed ID: 27033342
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?
Go AS; Hylek EM; Chang Y; Phillips KA; Henault LE; Capra AM; Jensvold NG; Selby JV; Singer DE
JAMA; 2003 Nov; 290(20):2685-92. PubMed ID: 14645310
[TBL] [Abstract][Full Text] [Related]
6. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation.
Yasaka M; Minematsu K; Yamaguchi T
Intern Med; 2001 Dec; 40(12):1183-8. PubMed ID: 11813841
[TBL] [Abstract][Full Text] [Related]
7. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group.
Yamaguchi T
Stroke; 2000 Apr; 31(4):817-21. PubMed ID: 10753981
[TBL] [Abstract][Full Text] [Related]
8. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Hylek EM; Go AS; Chang Y; Jensvold NG; Henault LE; Selby JV; Singer DE
N Engl J Med; 2003 Sep; 349(11):1019-26. PubMed ID: 12968085
[TBL] [Abstract][Full Text] [Related]
9. Warfarin anticoagulation intensity in Japanese nonvalvular atrial fibrillation patients: a J-RHYTHM Registry analysis.
Yamashita T; Inoue H; Okumura K; Atarashi H; Origasa H;
J Cardiol; 2015 Mar; 65(3):175-7. PubMed ID: 25169015
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Graham DJ; Reichman ME; Wernecke M; Zhang R; Southworth MR; Levenson M; Sheu TC; Mott K; Goulding MR; Houstoun M; MaCurdy TE; Worrall C; Kelman JA
Circulation; 2015 Jan; 131(2):157-64. PubMed ID: 25359164
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis.
Koretsune Y; Yamashita T; Yasaka M; Ono Y; Hirakawa T; Ishida K; Kuroki D; Sumida T; Urushihara H
J Cardiol; 2019 Mar; 73(3):204-209. PubMed ID: 30477926
[TBL] [Abstract][Full Text] [Related]
12. Use of warfarin for nonvalvular atrial fibrillation in nursing home patients.
Lackner TE; Battis GN
Arch Fam Med; 1995 Dec; 4(12):1017-26. PubMed ID: 7496550
[TBL] [Abstract][Full Text] [Related]
13. Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation.
Pengo V; Cucchini U; Denas G; Davidson BL; Marzot F; Jose SP; Iliceto S
Thromb Haemost; 2010 Feb; 103(2):442-9. PubMed ID: 20076843
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
Wang KL; Lopes RD; Patel MR; Büller HR; Tan DS; Chiang CE; Giugliano RP
Eur Heart J; 2019 May; 40(19):1492-1500. PubMed ID: 30590440
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.
Savarese G; Giugliano RP; Rosano GM; McMurray J; Magnani G; Filippatos G; Dellegrottaglie S; Lund LH; Trimarco B; Perrone-Filardi P
JACC Heart Fail; 2016 Nov; 4(11):870-880. PubMed ID: 27614940
[TBL] [Abstract][Full Text] [Related]
16. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Garcia DA; Fisher DA; Mulder H; Wruck L; De Caterina R; Halvorsen S; Granger CB; Held C; Wallentin L; Alexander JH; Lopes RD
Am Heart J; 2020 Mar; 221():1-8. PubMed ID: 31896036
[TBL] [Abstract][Full Text] [Related]
18. Long-term PT-INR levels and the clinical events in the patients with non-valvular atrial fibrillation: a special reference to low-intensity warfarin therapy.
Takarada K; Sato M; Goto M; Saito A; Ikeda Y; Fujita S; Fuse K; Takahashi M; Oguro T; Matsushita H; Kitazawa H; Okabe M; Abe H; Toba K; Yamashina A; Aizawa Y
J Cardiol; 2014 Aug; 64(2):127-32. PubMed ID: 24440439
[TBL] [Abstract][Full Text] [Related]
19. Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation.
Suzuki S; Yamashita T; Kato T; Fujino T; Sagara K; Sawada H; Aizawa T; Fu LT
Circ J; 2007 May; 71(5):761-5. PubMed ID: 17457005
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
